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We previously demonstrated that puriﬁed polyclonal and monoclonal anti-dsDNA antibodies bind a 15-mer peptide
ASPVTARVLWKASHV in ELISA and Dot blot. This 15-mer peptide partial sequence ARVLWKASH shares similarity with
burkholderia bacterial cytochrome B 561 partial sequence ARVLWRATH. In this study, we show that puriﬁed anti-dsDNA
antibodies react with burkholderia fungorum bacterial cell lysates in Western blot. We used anti-dsDNA antibodies to make an
anti-dsDNAantibodiesaﬃnitycolumnandusedthiscolumntopurifytheburkholderiafungorumbacterialprotein.Puriﬁedanti-
dsDNA antibodies bind speciﬁcally to puriﬁed bacterial antigen and puriﬁed bacterial antigen blocked the anti-dsDNA antibodies
binding to dsDNA antigen. Sera with anti-dsDNA antibodies bind speciﬁcally to puriﬁed bacterial antigen. We obtained protein
partial sequence of RAGTDEGFG which is shared with burkholderia bacterial transcription regulator protein sequence. Sera with
anti-dsDNA antibodies bind to RAGTDEGFG peptide better than control groups. These data support our hypothesis that the
origin of anti-dsDNA antibodies in SLE may be associated with burkholderia bacterial infection.
Copyright © 2008 W. Zhang and M. Reichlin. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Systemic lupus erythematosus (SLE) is an autoimmune
disease that aﬀects multiple organ systems. Although the
etiology of SLE, and of autoimmunity in general remain
unknown, considerable evidence has been accumulated on
the pathophysiologic mechanisms, which lead to the failure
of distinction between self and nonself and the production
of autoantibodies. Genetic, hormonal, and environmental
factors have been attributed roles in the etiology of autoim-
munity.
Antinuclear antibodies are a hallmark of SLE, whereas
anti-dsDNA antibodies are a very speciﬁc marker for this
disease. High-aﬃnity anti-dsDNA antibodies correlate with
disease activity, especially with renal involvement. Over the
past several years, it has been clearly demonstrated that anti-
dsDNA antibodies have pathogenic potential. Clinical data
demonstrate that anti-dsDNA antibody titers correlate with
diseaseactivityinasigniﬁcantnumberofpatientswithlupus
nephritis, and glomerular eluates from patients with active
lupus nephritis contain anti-dsDNA antibodies [1, 2].
The mechanisms responsible for the production of anti-
dsDNA antibodies are not understood. The search for cross-
reactive antigens continues, as these antigens may yield clues
to the origin and pathogenesis of anti-dsDNA antibodies.
A major goal of understanding of the structure, origin,
and pathogenicity of anti-dsDNA antibodies is to develop
novel targeted treatments for SLE.
In previous study, we used a patient anti-dsDNA
antibody to select phage clones and four positive clones
were found [3]. Those four clones sequence are clone B
(ASPVTARVLWKASHV), clone C (VSSLVLLSHGGPHSS),
clone D (IMVLCPLWLGTTS), and clone E (AVAHVTSR-
RVPRWSAA). We demonstrated that puriﬁed polyclonal
anti-dsDNA antibodies and a monoclonal anti-dsDNA anti-
body speciﬁcally bind a 15-mer clone B peptide ASPV-
TARVLWKASHV. This chemically synthesized peptide could
be recognized by anti-dsDNA antibodies in ELISA and Dot
blot [3].
The sequences of the four clones were loaded into
the National Center for Biotechnology Information (NCBI)
protein database to search for similarity to some protein2 Clinical and Developmental Immunology
sequence. It is of interest to ﬁnd that this 15-mer clone
B peptide partial sequence ARVLWKASH shares similar-
ity with burkholderia bacterial cytochrome B 561 partial
sequence ARVLWRATH (including Burkholderia fungorum,
Burkholderia dolosa, Burkholderia cenocepacia, Burkholde-
ria mallei, Burkholderia pseudomallei, Burkholderia thailan-
densis and Burkholderia cenocepaci). The clone C partial
sequence LVLLSHGGPH shares sequence with burkholderia
bacterial transcriptional regulator partial sequence.
In this study, we have examined anti-dsDNA antibodies
from SLE patient’s sera to see whether they can react with
Burkholderiabacterialprotein.Wehavepuriﬁedandisolated
bacterial protein and sequenced these proteins. Synthetic
peptides have been prepared to conﬁrm that anti-dsDNA
antibodies can bind these antigens in vitro. A possible link
between an immune response to burkholderia and anti-
dsDNA antibody production in lupus patients has been
investigated.
2. MATERIALS AND METHODS
2.1. Patientdata
Human sera used in this study were collected from SLE
patients and CFII from Sigma (St. Louis, Mo, USA) was
used as control antibody. All 30 SLE patients satisﬁed
American College of Rheumatology revised criteria for the
classiﬁcation of SLE [4]. SLE sera were assayed for the
quantity of anti-dsDNA by ELISA and Crithidia luciliae anti-
dsDNA antibody test kit from HELIX diagnostic (Madison,
WI). All 30 SLE patients have anti-dsDNA antibodies.
2.2. PreparationofIgGanti-dsDNAantibodyand
Biopanningofphagedisplayrandompeptide
librariesbyanti-dsDNAantibodies
The IgG fraction from anti-dsDNA positive sera was isolated
by chromatography on DE-52 and protein A-sepharose
(Sigma) [3]. Puriﬁed IgG from either DE-52 or protein A
was passed through a dsDNA aﬃnity column (Sigma). The
c o l u m nw a sw a s h e dw i t hT r i sb u ﬀered saline (PH 7.4), and
bound protein was eluted with 3M MgCl2. The puriﬁed
antibodies were assayed for quantity of anti-dsDNA by
ELISA and Crithidia luciliae anti-dsDNA antibody test kit
(HELIX diagnostic).
A 15-mer peptide library display on gene VIII product of
fd phage [5] was used in the study. This library was gener-
ously provided by Dr. G. P. Smith (University of Missouri,
Columbia, Mo, USA). The basic methods of screening were
adapted from the previous reports [6, 7]. Three rounds of
screening were performed with the biotinylated anti-dsDNA
antibodies. For the ﬁrst round of selection, 10ug of biotiny-
lated anti-dsDNA antibodiesin 400μLo f0 . 5χTBST (25mM
Tris, 75mM NaCl and 0.05% Tween 20, pH 7.5) containing
1mg/mL BSA were immobilized onto a streptavidin-coated
petri dish by incubation for 2 hours at room temperature.
The phage suspension library was added and incubated out
4 hours at room temperature. After the removal of unbound
phage by washing 10 times with 0.5 χTBST, the bound phage
was recovered using elution buﬀer (0.1N HCl-glycine, pH
2.2,). The eluates were immediately neutralized using 2M
Tris. Eluted phage was ampliﬁed in Escherichia coli K91 Kan
and used as input in the subsequent rounds of selection.
After three rounds of selection, phage clones harvested
from the third round output were randomly selected and
propagated in 1.5 mL of terriﬁc broth [1.2% (w/v) bacto-
tryptone, 2.4% (w/v) yeast extract, 0.4% (v/v) glycerol,
17mM KH2PO4 and 72mM K2HPO4] supplemented with
20ug/mLtetracyclineat37◦Cfor20hours.Thecultureswere
clariﬁed at 2500g for 10 minutes. The supernatants were
recovered for the selection of anti-dsDNA antibody binding
clones and subsequent DNA sequencing.
3. WESTERN BLOT
Burkholderia fungorum bacterial cells were purchased from
ATCC. These bacteria in BBL trypticase soy broth (Becton,
Dickinson and Company, Sparks, Md, USA) were cultured
overnight at 37◦C[ 8]. The bacterial cell lysates were applied
to12.5%SDS-PAGEgel.Afterelectrophoreticseparation,the
proteins were transferred to a nitrocellulose membrane. The
nitrocellulose membrane was used for screening antibodies
reactive with Burkholderia fungorum bacterial proteins.
3.1. PreparationofIgGanti-dsDNAantibodycolumn
andpuriﬁcationofproteinsfromBurkholderia
fungorumbacterialcelllysates
A puriﬁed IgG anti-dsDNA antibody preparation which
bound to Burkholderia fungorum bacterial protein was used
to prepare an anti-dsDNA antibody aﬃnity column. Puriﬁed
anti-dsDNA antibodies were coupled to CNBr-activated
sepharose 4B [9]. The Burkholderia fungorum bacterial
lysates were passed through an anti-dsDNA antibody aﬃnity
column. The column was washed with Tris buﬀered saline
(PH 7.4), and bound protein was eluted with 3M MgCl2.
3.2. PuriﬁedhumanIgGanti-dsDNAantibodies
bindingtopuriﬁedburkholderiafungorum
bacterialantigen
IMMULON plates from Thermo Scientiﬁc (Milford, MA,
USA) were used to detect the binding of 5 aﬃnity puriﬁed
human IgG anti-dsDNA antibodies isolated from SLE
patients sera. In addition, one human IgG anti-dsDNA
monoclonal antibody, and normal IgG as control were
assessed for binding to the puriﬁed burkholderia fungorum
bacterial antigen. The ELISA plate was coated with puriﬁed
bacterial antigen (50ug/mL) and puriﬁed anti-dsDNA Ab
(1ug/100uL) was applied to the plate. Binding of IgG was
detected using goat antihuman IgG Fc fragment speciﬁc
alkaline.
3.3. Inhibitionofanti-dsDNAbindingtodsDNA
antigenbythepuriﬁedbacterialantigen
Reaction mixtures of anti-dsDNA antibody at the same
concentration and the puriﬁed bacterial antigen at varyingW. Zhang and M. Reichlin 3
concentrations were prepared. The ELISA plate was coated
with dsDNA (50ug/mL). After the puriﬁed bacterial antigen
was incubated for two hours with anti-dsDNA antibodies at
RT, the reaction mixture was transferred to dsDNA-coated
wells. The amount of human antibodies bound to the plate
was determined by using an antihuman IgG Fc speciﬁc
alkaline phosphatase conjugate (Sigma). Following another
washing, the substrate was added to the plate for color
development.
3.4. Serumbindingtopuriﬁedbacterialantigen
IMMULON plates were used to detect three groups of sera;
30SLEpatients’sera,secondly60controlserathatinclude15
rheumatoid arthritis sera, 15 polymyositis dermatomyositis
sera, 15 sclerodema sera, 15 anti-Ro/anti-La positive sera,
and thirdly 30 normal sera. The plates were coated with
puriﬁed bacterial antigen (50ug/mL) and incubated at 4◦C
overnight. The wells were washed and treated with blocking
solution. Sera diluted 1/100 with PBS were added to the
peptide-coated wells and incubated for 2 hours at room
temperature. After washing, binding of IgG was detected
using goat antihuman IgG Fc fragment speciﬁc alkaline
phosphatase conjugate (Sigma).
4. PROTEIN SEQUENCING
The eluate from the anti-dsDNA antibody column was
applied to 12.5% SDS-PAGE gel and then electrotransferred
to PVDF membranes [10]. Proteins bound to PVDF were
stained by Coomassie Blue R-250. The stained protein band
was excised with a clean razor blade. The protein sequence
was determined by Oklahoma University Health Center
Molecular Biology-Proteomics Facility.
4.1. Peptidesynthesis
A protein partial sequence of RAGTDEGFG from the bacte-
rial protein band in PVDF was obtained. The RAGTDEGFG
sequence is shared with burkholderia bacterial transcription
regulator protein sequence.The peptide RAGTDEGFG and
a scrambled form as control peptide FGAGTRDGE were
synthesized by the Molecular Biology Resource Facility,
University of Oklahoma Health Sciences Center. The purity
of the peptides was =>90% by reverse phase HPLC and the
compositions were conﬁrmed by amino acid analysis.
4.2. PuriﬁedhumanIgGanti-dsDNAantibodies
bindingtosyntheticpeptide
IMMULON plates were used to detect the binding of 5 aﬃn-
itypuriﬁedhumanIgGanti-dsDNAantibodiesisolatedfrom
SLE patients sera. In addition, one human IgG anti-dsDNA
monoclonal antibody, and normal IgG as control were
assessed for binding to the synthetic peptide (RAGTDEGFG)
and control peptide (FGAGTRDGE). The ELISA plate was
coated with synthetic peptide (50ug/mL) and puriﬁed anti-
dsDNA antibody (1ug/100uL) was applied to the plate.
Binding of IgG was detected using goat antihuman IgG Fc
fragment speciﬁc alkaline phosphatase conjugate (Sigma).
4.3. Inhibition
Inhibition of anti-dsDNA binding to dsDNA antigen by the
synthetic peptide.
Reaction mixtures of anti-dsDNA antibody at the same
concentration and the synthetic peptide at varying concen-
trations were prepared. The ELISA plate was coated with
dsDNA (50ug/mL). After the synthetic peptide (RAGT-
DEGFG) was incubated for two hours with anti-dsDNA
antibodies at RT, the reaction mixture was transferred to
dsDNA coated wells. The amount of human antibodies
bound to the plate was determined by using an antihuman
IgG Fc speciﬁc alkaline phosphatase conjugate (Sigma).
Following another washing, the substrate was added to the
plate for color development.
4.4. Serumbindingtosyntheticpeptides
IMMULON plates were used to detect two groups of sera;
30 SLE patients’ sera and 60 control sera that include 15
rheumatoid arthritis, 15 polymyositis dermatomyositis, 15
sclerodema, 15 anti-Ro/anti-La positive sera, and 30 normal
sera. The plates were coated with peptide RAGTDEGFG
(100ug/mL) and incubated at 4◦C overnight. The wells were
washed and blocked with blocking solution. Sera diluted
1/100 with PBS were added to the peptide-coated wells and
incubated for 2 hours at room temperature. After washing,
binding of IgG was detected using goat antihuman IgG Fc
fragment speciﬁc alkaline phosphatase conjugate (Sigma).
5. RESULTS
5.1. Detectionofanti-dsDNAantibodyreactionwith
burkholderiafungorumbacterialcelllysatesby
WesternBlot
12 SLE patients sera with anti-dsDNA antibodies were used
as a sourcefor the aﬃnity puriﬁcation ofantibodies. Wepur-
chased burkholderia fungorum bacterial cells from ATCC.
We tested 12 puriﬁed anti-dsDNA antibodies from SLE
patientsandfoundthatsevenofthesepuriﬁedantibodiescan
bindtheburkholderiafungorumbacterialproteininWestern
Blot (Figure 1).
5.2. Puriﬁedbacterialproteinfrom
burkholderiafungorum
We used one of the SLE patients anti-dsDNA antibodies that
reacts with the burkholderia fungorum bacterial protein to
make an anti-dsDNA antibody aﬃnity column. We used this
aﬃnity column to purify the burkholderia fungorum bacte-
rial protein. We found that puriﬁed burkholderi fungorum
bacterialproteincontainstwomajorbandsin12.5%SDSgel.
One is about 35KD and another one is about 25KD, as seen
in Figure 2. We tested 4 puriﬁed anti-dsDNA antibodies for
binding with the burkholderia fungorum bacterial protein4 Clinical and Developmental Immunology
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Figure 1: 12 puriﬁed anti-dsDNA antibodies from SLE patients.
Seven of these puriﬁed antibodies can bind a 35KD burkholderia
fungorum bacterial protein in Western Blot.
35KD
25KD
Figure 2: Burkholderia fungorum bacterial protein puriﬁed by
anti-dsDNA antibodies aﬃnity column. The eluate from the
column was examined by 12.5% SDS gel. The result shows that
puriﬁed proteins contain two major bands, one is 35KD bacterial
protein and the other one is 25KD bacterial protein.
by ELISA. All 4 anti-dsDNA antibodies were reactive with
theburkholderiafungorumbacterialprotein,andthecontrol
IgG was very weakly reactive (Figure 3). The burkholderia
fungorum bacterial protein was studied for the ability to
inhibit anti-dsDNA antibody activity. As seen in Figure 4,
anti-dsDNAantibodypreparationsboundtodsDNAantigen
can be inhibited by the bacterial protein. We tested the SLE
sera, control sera, and normal sera. As seen in Figure 5, the
burkholderia fungorum bacterial protein was reactive with
SLE sera with anti-dsDNA antibodies. The reaction can be
blockedbydsDNAantigen.Incontrolsera,somerheumatoid
arthritis sera with anti-ssDNA antibodies were reactive to
burkholderia fungorum bacterial protein. We picked these
sera and did inhibition by ssDNA and synthesized peptide.
TheresultshowsthatreactioncanbeblockedbyssDNAanti-
gen. The diﬀerences in means of OD410 reading between the
SLE sera (mean = 0.7617, N = 30) and normal sera (mean
= 0.2320, N = 30) when they bound to the bacterial antigen
werestatisticallycomparedbyt-test(usingGraphPadprism),
and the diﬀerences were very signiﬁcant (P<. 0001).
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Figure 3: Testing 4 aﬃnity puriﬁed human IgG anti-dsDNA
antibodies in binding to the puriﬁed bacterial antigen in ELISA.
ELISA plates were coated with the puriﬁed bacterial antigen
(50μg/mL). Lanes 1–4 contain puriﬁed anti-dsDNA antibodies
(1μg/100μL) binding to puriﬁed bacterial antigen and lane 5 has
CF II as control binding to puriﬁed bacterial antigen. Anti human
IgG Fc fragment speciﬁc alkaline phosphatase conjugate was used
to detect anti-dsDNA antibody binding. The data were expressed as
the mean ± SD.
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Figure 4: Inhibition of anti-dsDNA antibodies binding to dsDNA
antigen by puriﬁed bacterial antigen. ELISA plates were coated
with dsDNA (50μg/mL). Lane 1, 2, and 3 are three diﬀerent
patients anti-dsDNA antibodies. The light column shows the
patient puriﬁed anti-dsDNA antibodies (1.25μg/100uL) binding to
dsDNA antigen, and dark column shows the patient puriﬁed anti-
dsDNA antibodies (1.25μg/100uL) mixed with puriﬁed bacterial
antigen(10μg/100uL). The data were expressed as the mean ± SD.
5.3. Sequenceanalysisof25KDand
35KDbacterialproteins
The electrophoresed puriﬁed burkholderia fungorum pro-
teins from an anti-dsDNA aﬃnity column were transferredW. Zhang and M. Reichlin 5
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Figure 5: Reaction of SLE sera and control sera with the puriﬁed
bacterial antigen. The sera were 1/100 in PBS and added into
puriﬁed bacterial antigen-coated ELISA plates and the reaction of
sera antibodies with the puriﬁed bacterial antigen were detected by
goat antihuman IgG Fc fragment speciﬁc alkaline phosphatase con-
jugate. The 30 SLE sera and the control sera include 15 rheumatoid
arthritis, 15 polymyositis dematomyositis, 15 sclerodema, 15 Ro/La
positive sera, and 30 normal sera. The mean reading of 30 SLE sera
boundwithpuriﬁedbacterialantigenwasstatisticallydiﬀerentfrom
that of control sera (P<. 0001 by unpaired t-test).
ontopolyvinyl diﬂuoride (PVDF)membranes.The bacterial
proteins were screened by Western Blot using anti-dsDNA
antibodies. The two immunoreactive bands (25KD and
35KD) were excised from the PVDF and sequenced. A
protein partial sequence of RAGTDEGFG from the protein
band is shared with burkholderia bacterial transcription
regulator protein sequence.
5.4. Conﬁrmingthebindingofanti-dsDNAantibodies
tothepeptidebychemicalsynthesisofpeptides
RAGTDEGFG peptide which is shared with burkholderia
bacterial transcription regulator protein sequence was syn-
thesized. We tested 4 puriﬁed anti-dsDNA antibodies for
binding with the RAGTDEGFG peptide by ELISA. All 4 anti-
dsDNA antibodies were reactive with the synthesized pep-
tide, and the control IgG was very weakly reactive (Figure 6).
We also compared RAGTDEGFG peptide with scramble
control peptide FGAGTRDGE. Anti-dsDNA antibodies were
more strongly reactive with RAGTDEGFG peptide than
scrambled control peptide FGAGTRDGE.
5.5. Inhibitionassay
The synthesized peptide (RAGTDEGFG) was studied for
the ability to inhibit anti-dsDNA antibody activity. As seen
in Figure 7, anti-dsDNA antibody preparations bound to
dsDNA antigen can be inhibited by the synthetic peptide.
5.6. BindingofSLEserawithsynthesizedpeptide
RAGTDEGFGinELISA
We tested the SLE sera, control sera, and normal sera, as seen
in Figure 8. The synthetic peptide was reactive with SLE sera
0
0.2
0.4
0.6
0.8
1
1.2
1.4
O
D
4
1
0
n
m
123 45
Figure 6: Testing 4 aﬃnity puriﬁed human IgG anti-dsDNA
antibodies in binding to the synthetic peptide in ELISA. ELISA
plates were coated with synthetic peptide (100μg/mL). Lanes 1–4
contain puriﬁed anti-dsDNA antibodies (1μg/100μL) binding to
syntheticpeptideandlane5hasCFIIascontrolbindingtosynthetic
peptide. Antihuman IgG Fc fragment speciﬁc alkaline phosphatase
conjugate was used to detect anti-dsDNA antibody binding. The
data were expressed as the mean ± SD.
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
O
D
4
1
0
n
m
123
Figure 7: Inhibition of anti-dsDNA antibodies binding to dsDNA
antigen by synthetic peptide (RAGTDEGFG). ELISA plates were
coated with dsDNA (50μg/mL). Lane 1, 2, and 3 are three diﬀerent
patients anti-dsDNA antibodies. The light column shows the
patient puriﬁed anti-dsDNA antibodies (1.25μg/100uL) bind to
dsDNA antigen, and dark column shows the patient puriﬁed anti-
dsDNA antibodies (1.25μg/100uL) mixed with synthetic peptide
(3.4μg/100uL). The data were expressed as the mean ± SD.6 Clinical and Developmental Immunology
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Figure 8: Reaction of SLE sera and control sera with the peptide.
The sera were diluted 1/100 in PBS and added to peptide-coated
ELISA plates and the reaction of sera antibodies with the peptide
were detected by goat antihuman IgG Fc fragment speciﬁc alkaline
phosphatase conjugate. The 30 SLE sera and the control sera
include 14 rheumatoid arthritis, 12 polymyositis dematomyositis,
14 sclerodema, 15 Ro/La positive sera, and 30 normal sera. The
mean reading of 30 SLE sera bound with peptide was statistically
diﬀerent from that of control sera (P<. 0001 by unpaired t-test).
with anti-dsDNA antibodies. The reaction can be blocked by
dsDNA antigen. In control sera, some sera with anti-ssDNA
antibodies were reactive to synthesized peptide. We picked
these sera and did inhibition by ssDNA and synthesized
peptide. The results show that reaction can be blocked by
ssDNA antigen. The diﬀerences in means of OD410 reading
between the SLE sera (mean = 1.015, N = 30) and normal
sera (mean = 0.2513, N = 30) when they bound to the
synthetic peptide were statistically compared by t-test (using
GraphPad prism), and the diﬀerences were very signiﬁcant
(P<. 0001). The diﬀerences in means of OD410 reading
between the SLE sera (mean = 1.015, N = 30) and control
sera (mean = 0.3383, N = 60) when they bound to the
synthetic peptide were statistically compared by t-test (using
GraphPad prism), and the diﬀerences were very signiﬁcant
(P<. 0001).
6. DISCUSSION
Environmental pathogens have long been suspected to be
inducers of autoimmune disease. Autoimmune NZB mice
raised in a germ-free environment develop reduced titers
of auto-antibodies, and elevated titers of anti-dsDNA anti-
bodies can be found in patients with microbial infections,
suggesting that microbial stimulation of the immune system
helps stimulate the induction of auto-antibodies in some
way [11, 12]. Anti-dsDNA antibodies derived from na¨ ıve
lupus prone mice can bind to the cell surfaces of murine
endogenous microbial ﬂora [13]. Monoclonal anti-dsDNA
antibodies derived from mice and humans with SLE bind to
theglycolipidcomponentsofthemycobacterialcellwall[14],
suggesting that bacterial antigens may elicit these antibodies.
This crossreactivity, known as molecular mimicry, oﬀers a
potential explanation for the development of autoimmunity.
In a previous study, we demonstrated that puriﬁed
anti-dsDNA antibodies speciﬁcally bind a 15-mer peptide
ASPVTARVLWKASH [3], and the 15-mer peptide partial
sequence ARVLWKASH is shared with burkholderia bac-
terial cytochromeB 561 partial sequence ARVLWRATH.
Burkholderia bacteriaare rod-shaped, motile, gram-negative
bacteria that includes both human and plant pathogens
as well as environmentally important bacteria. The genus
Burkholderia currently comprises 19 named species [8].
The clinical signiﬁcance of Burkholderia cepacia, originally
described as a plant pathogen in the 1950s [15], increased
in the 1980s as it emerged as an opportunistic pathogen,
colonizing the lungs of cystic ﬁbrosis patients [16–18],
and immunocompromised individuals [19–21]. At its peak
incidence in the mid 1980s, 20% of colonized patients
suﬀered from severe progressive respiratory failure with
bacteremia which was often fatal [16, 22].
In this study, we have demonstrated that puriﬁed anti-
dsDNA antibodies from lupus patients can react with
burkholderia fungorum bacterial cell lysates in Western blot.
We used one of the SLE patients anti-dsDNA antibodies that
reacts with the burkholderia fungorum bacterial protein to
make an anti-dsDNA antibodies aﬃnity column. We used
this aﬃnity column to purify the burkholderia fungorum
bacterial protein. We found that puriﬁed burkholderi fun-
gorum bacterial protein contains two major bands in 12.5%
SDS gel, one is about 35KD and the other one is about
25KD. We tested puriﬁed human anti-dsDNA antibodies
binding to puriﬁed bacterial antigen compared with normal
IgG binding. We also used puriﬁed bacterial antigen to
block the anti-dsDNA antibodies binding to dsDNA antigen.
The results show that anti-dsDNA antibody binding to
puriﬁed bacterial antigen is speciﬁc. We tested 3 groups of
sera for binding studies with the puriﬁed bacterial antigen.
The results show that sera with anti-dsDNA antibodies
bind to puriﬁed bacterial antigen more strongly than other
control groups. We obtained protein partial sequence of
RAGTDEGFG which is shared with burkholderia bacterial
transcription regulator protein sequence. We tested 3 groups
of sera for binding studies with the RAGTDEGFG peptide.
The results show that sera with anti-dsDNA antibodies bind
to RAGTDEGFG peptide and are higher than other control
groups. In a previous study, we used a patient anti-dsDNA
antibody to select phage clones and four positive clones
were found [3]. Those four clones sequences are clone B
(ASPVTARVLWKASHV), clone C (VSSLVLLSHGGPHSS),
clone D (IMVLCPLWLGTTS), and clone E (AVAHVTSR-
RVPRWSAA). The clone B partial sequence ARVLWKASH is
shared with burkholderia bacterial cytochromeB 561 partial
sequence. The clone C partial sequence LVLLSHGGPH
is shared with burkholderia bacterial transcriptional reg-
ulator partial sequence. We used the same patient’s anti-
dsDNA antibody to make an antibody aﬃnity column
for puriﬁed burkholderia bacterial protein. We obtained
protein partial sequence of RAGTDEGFG which is shared
with burkholderia bacterial transcription regulator protein
sequence, but we did not obtain burkholderia bacterial
cytochrome B561 protein sequence from puriﬁed bacterial
antigen. It is possible that the anti-dsDNA antibody aﬃnityW. Zhang and M. Reichlin 7
column can not eﬃciently isolate enough burkholderia
bacterial cytochrome B561 protein for sequencing. We also
compared burkholderia bacterial cytochrome B561 protein
(186 amino acids) with burkholderia bacterial transcription
regulator (308 amino acids) protein sequence. The two
proteins sequences share 29 amino acids and 20 amino
acid positions have the same charge. These data support
our hypothesis that the origin of anti-dsDNA antibodies in
SLE may be associated with burkholderia bacterial infection.
The burkholderia bacterial infection is an environmental
risk factor that may be most closely associated with SLE.
The development of auto-antibodies is a common feature
in autoimmune diseases. Interactions between auto-antigens
and auto-antibodies have to date mainly been analyzed
by truncated subclones or synthetic peptides mimicking
the proposed target epitopes. However, recent ﬁndings
and reviews have implied that most autoepitopes may be
conformation-dependent [23], thus stressing the need to
develop procedures to analyze in detail which functional
domain of the auto-antigen could be immunodominant.
Immunization of non-autoimmune mice with Burkholderia
antigensanditsselectedpeptideswouldsupportourhypoth-
esis if autoimmunity is induced.
Clearly, other environmental factors such as Epstein-barr
virus infection [24, 25]a sw e l la sg e n e t i ca n di m m u n o l o g i c
factors may also be important. Continued eﬀorts in this
sphere include the possible development of an animal model
that could provide fruitful areas of investigation.
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